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Effects of Levodopa on Speech Intensity and Rate in Parkinson’s Disease 
Background Results
Conclusions
• Levodopa is the primary medication for the treatment of general 
limb motor symptoms in Parkinson’s disease (PD), however its 
effects on speech intensity and rate have been inconsistent 1,2,3.
• Two recent studies of the effects of levodopa on dysphonia and 
speech disfluency found that responsiveness was significantly 
associated with the severity of these speech symptoms 4,5.
• Duration of PD diagnosis and duration of levodopa use may affect 
the response to levodopa and its effects on speech. It has been 
suggested that speech becomes levodopa resistant, particularly 
after 10 years of use6,7.
Objectives
To examine the effects of levodopa on speech intensity and speech 
rate and to explore the potential association between levodopa 
responsiveness and the severity of these speech symptoms in PD.
• 54 individuals with PD (IWDPs) and 11 age-matched healthy 
controls (HC) participated in this study.
• IWPDs were evaluated OFF-medication, at least 12 hours after 
their last dose of levodopa. After testing, IWPDs took a controlled 
dose of 300 mg of levodopa. ON-medication condition testing 
began 1 hour after this dose.
• IWPDs had a mean age of 65.94 years (SD =7.38, range 47-82 
years). Demographic information is presented in Table 1. Controls 
have a mean age of 62.09 years (SD = 6.55, range 52-72).
• Speech tasks were categorized as: 1) syllable repetition (10x of 
puh, tuh, kuh, 5x ai slow and fast), 2) reading sentences (the 
Rainbow passage and the Patty sentence.
• Praat was used to obtain average speech intensity (dB SPL) and 
duration (ms) of each speech task (the first 5 or 10 syllables of 
each syllable repetition task and each of the 4 selected sentences). 
• T-tests and correlations were used to evaluate differences between 
groups/medication conditions and associations between selected 
variables.
Mean (SD) Range
Age 65.94 (7.38) 47-82
Duration of diagnosis 9.15 (4.18) 2-16
Duration of levodopa use 7.45 (3.86) 2-16
UPDRS OFF-medication 29.94(8.39) 14-51
UPDRS ON-medication 16.25 (7.12) 3-32
Levodopa equivalent dose 1027.2 (449.2) 300-2200
Table 1. Demographic information for IWPDs
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Levodopa and Speech Intensity 
• Administration of levodopa medication produced a significant increase in speech intensity in the IWPD group, illustrated in Table 2.
• Negative correlations suggest that IWPDs with more severe (lower) speech intensity may experience a larger medication-related increase than those with less 
severe (higher) speech intensity (Figure 1). 
• IWPDs were split into Severe “Low Intensity” and Mild “High Intensity” groups based on their OFF-medication speech intensity relative to the HC intensity average.
• Individuals were divided based on a cut-off score 2SD below the average HC speech intensity.
• The Severe group had significantly larger medication-related (improvement) in speech intensity (Figure 2).
Levodopa and Speech Time/Rate
• Levodopa was not found to significantly affect speech time/rate in the PD group. IWPDs were not found to be significantly different from controls (Table 3).
• The significant negative correlations suggest that IWPDs with slower rate of speech experience a larger medication-related change in speech time than those who 
speak faster (Figure 3).
• IWPDs were split into ”Fast” and “Slow” subgroups based on their OFF-medication speech time relative to the HC average speech time (-1SD).
• The Slow group had significantly larger medication-related (improvement), relative to the Fast group, for several of the speech tasks (Figure 4 and 5).









ppp10 66.97 (3.72) 68.37 (4.44) .005* 69.45 (4.31) .028*
kkk10 66.24 (4.17) 67.53 (4.09) .002* 68.97 (3.95) .025*
aiFast 71.25 (4.19) 72.92 (4.36) .000* 72.49 (3.88) .183
Rain1 66.12 (4.12) 67.03 (4.61) .052 68.99 (3.31) .017*
Rain3 64.57 (3.86) 65.70 (4.45) .006* 67.44 (2.85) .012*
Table 2. Means and standard deviations of speech intensity 
Figure 1. Scatterplot of medication-related change in 
intensity vs. the OFF-medication speech intensity 










ttt10 1.90 (.43) 1.83 (0.32) .182 1.71 (.28) .147
aiSlow 0.91 (.22) 0.86 (0.20) .058 0.99 (.23) .274
Patty 2.03 (0.28) 2.02 (0.31) .548 2.04 (0.29) .983
Rain2 3.83 (1.13) 3.91 (1.18) .404 3.66 (0.54) .614 Figure 3. Scatterplot of medication-related change vs. 
the OFF-medication speech time/rate
Table 3. Means and standard deviations of speech time/rate 
Figure 4. Average levodopa medication-related change in 
speech rate for Fast and Slow subgroups
Figure 5. Average levodopa medication-related change in 
speech rate for Fast and Slow subgroups
Methods Figure 2. Average levodopa medication-related change in 
speech intensity for Mild and Severe subgroups
• In this group of IWPDs, levodopa had a significant effect 
on speech intensity but not speech time/rate. However,  
variation in severity appeared to influence the results.
• An important relationship was observed between the 
medication-related changes in speech intensity/rate and 
the OFF-medication severity of these symptoms.
• This study provides additional support for the “Speech 
Severity Responsiveness Hypothesis” which proposed that 
individuals with more severe speech symptoms show a 
greater degree of response to levodopa medication.
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